Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Zafatek

- PMLiVE

Takeda’s zasocitinib shows high rates of skin clearance in phase 3 psoriasis studies

Globally, an estimated 64 million people have psoriasis, with about 80-90% of those having plaque psoriasis

- PMLiVE

Takeda’s new study data for oveporexton shows improvements in narcolepsy type 1

The phase 3 results show improvements in daily function, cognition and nighttime sleep

- PMLiVE

GSK announces bepirovirsen’s ‘functional cure’ data to treat chronic hepatitis B

Over 240 million people worldwide live with chronic hepatitis B

- PMLiVE

GSK signs agreement with Protas to streamline clinical trials

The new three-year agreement builds on an existing two-year relationship

- PMLiVE

Novo Nordisk and Vivtex partner in deal worth up to $2.1bn

The companies aim to develop next-generation oral medicines for obesity and diabetes

- PMLiVE

GSK to acquire 35Pharma for $950m including a potential drug for pulmonary hypertension

PH has a five‑year survival rate of only around 50% and affects up to 82 million people worldwide

- PMLiVE

Novo Nordisk and Aspect Biosystems expand collaboration on diabetes research

The companies are working together on cellular medicines to boost, replace or repair biological functions

- PMLiVE

GSK’s Arexvy RSV vaccine receives expanded EC approval for use in adults

RSV affects approximately 64 million people around the world each year

- PMLiVE

Takeda’s zasocitinib demonstrates positive results in plaque psoriasis

Around 64 million people worldwide live with psoriasis

- PMLiVE

GSK’s Nucala approved by MHRA for uncontrolled COPD

Symptoms of COPD include breathlessness, persistent cough and frequent chest infections

- PMLiVE

GSK’s Blenrep approved by FDA for multiple myeloma

Approval supported by positive results from phase 3 trial

- PMLiVE

BMS, Takeda and Astex join AI training consortium

The initiative focuses on training AI models to aid in drug discovery and development

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links